Clinical

Using mass-spectrometry—based phosphoproteomics, researchers at the Moffit Cancer Center have identified a mechanism by which BRAF/PTEN-null melanoma cells develop resistance to BRAF inhibitors.

In a national study that included 9 million Americans, researchers found that the hospital a patient experiencing post-surgical complications returns to for readmission has an impact on the quality of care the patient receives.

Earlier this week, the FDA heard from various stakeholders and experts from the healthcare industry on how delays in the generic approval process impact healthcare costs.

Researchers at the University of Pennsylvania correlated data from Geographic Information Systems, hospital referral regions, census data, and CDC's State Cancer Profiles, to evaluate whether geographic barriers can prevent access to gynecologic cancer care.

A study published in PLOS ONE found that a higher intake of dietary trans fat correlated with memory loss in men 45 years old and younger.

Despite the increased use of breast-conserving therapy among women with early-stage breast cancer, many women continue to undergo mastectomy, according to a study from researchers at the University of Texas MD Anderson Cancer Center in Houston published in JAMA Surgery.

Scientists at Institut Pasteur in France have repurposed DPP4 inhibitors, used to treat type 2 diabetes mellitus, to boost the body's immune response to tumors.

A report by the American Cancer Society, published in JAMA Internal Medicine, finds smoking significantly increases the risk of cancer-related death.

The findings of inadequate access to providers and outdated information were no surprise to healthcare advocates. Many of the issues are addressed in a giant proposed rule issued by CMS in late May.

Another 2 companies that are using natural language processing and artificial intelligence in their efforts on direct-to-person health coaching.

Published in the Journal of the American Pharmacists Association, the study found a significant improvement in the blood pressure of T2DM patients who were counseled by a pharmacist.

The consensus that drug manufacturers are at fault for high prescription prices comes even though only half the respondents said they were taking medication themselves.

Scientists have identified 3 gene variants of HOXD9, which can help explain the development of ovarian cancer.

A paper published in the British Medical Journal, authored by FDA staff, compares content from FDA's complete response letter for a rejected drug, with the subsequent press release by drug developers.

The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced risk of hemorrhage

Statins have been the mainstay of LDL cholesterol management for 20 years, but can the PCSK9 inhibitors do more for some patients?

Integrating behavioral health care into the space where care for diabetes occurs can be aided by new delivery models and by technology, panelists say.

The FDA plans to mine data submitted by patients on the site PatientsLikeMe.

With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood in making treatment decisions. In a special issue on cardio-oncology in Evidence-Based Oncology, a publication of The American Journal of Managed Care, Texas Oncology's Dr. Debra Patt discusses the challenge of translating what is known from clinical trials to real-world patients, who may be older and have more health problems.

A Women's Health Initiative clinical trial has found that overweight or obese postmenopausal women are at an increased risk of aggressive breast cancer.

Glooko, a mobile support platform for diabetes care, helps fill the gaps created by the shortage of endocrinologists. Self-care is key to reducing the number of hypoglycemia incidents.

Combination therapy in diabetes care can offer benefits but might not be right for certain populations or at certain stages of care.

Trials that lead to FDA approval provide payers little information about the comparative differences between new therapies, and especially for their value for individual patients.

A study published in the Medical Journal of Australia found that a TV program questioning the link between statin use and cholesterol reduction resulted in more than 60,000 Australians reducing or discontinuing the medication.

With a growing world population and a growing proportion of elderly, more people are living in suboptimal health around the world. A third of the world's population experienced more than 5 ailments in 2013, according to a study published in The Lancet.

With more patients surviving cancer comes more effort to ensure that treatment itself does not shorten life, especially by damaging the heart. A special issue of Evidence-Based Oncology that takes a look at the growing specialty of cardio-oncology starts with a feature on the program at Massachusetts General Hospital.

This week the American Diabetes Association Scientific Sessions was held in Boston with results on 2 cardiovascular outcomes trials for diabetes drugs, and FDA advisory panels voted in favor of 2 PCSK9 inhibitors.

The House Energy and Commerce Committee is drafting language that will help create an in vitro center within the FDA to define risk categories for laboratory-developed tests (LDTs), and set timelines to accelerate the approval process for LDTs.

Considerations such as the potency of the drug, the practicality of the regimen, and the price go into decision-making.

What patients have heard from others with diabetes matters when they receive a diagnosis, according to the opening speaker at Patient-Centered Diabetes Care 2015.